Director, Enterprise Employer Access - Cell Therapy

Working with Us Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible. Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us. SUMMARY: The Director, Enterprise Employer Access - Cell Therapy is responsible for establishing early, upstream engagement across the employer benefit decision landscape to influence benefit design decisions for CAR-T and future cell and gene therapies both directly with employers and indirectly through the consultants, TPAs, and specialty vendors that shape those decisions, before carve-outs, COE mandates, or restrictive site-of-care requirements are finalized. This role addresses a critical access gap created by the shift of benefit decision-making authority from payers to employers by proactively engaging the stakeholders who define benefit philosophy upstream. The objective is to protect patient access, preserve provider flexibility, and support long-term enterprise value before coverage parameters are locked in. As employers increasingly serve as the ultimate decision-makers for high-cost therapies, often delegating execution to intermediaries, downstream payer influence becomes limited or nonexistent once benefit design decisions are finalized. This role ensures the organization is present where and when influence is exerted, shaping benefit strategy early rather than relying on reactive, exception-based access remediation later. RESPONSIBILITIES: ### Employer & Benefit-Decision Influencer Engagement: * Lead upstream engagement with the decision networks that shape employer coverage and utilization decisions for cell and gene therapies, including: * Large self-insured employers (where direct engagement is feasible) * National and regional benefits consultants * Third-party administrators (TPAs) * Specialty benefit managers and cell carve-out vendors * Employer-facing clinical, navigation, and care management partners * Build and manage a prioritized portfolio of employer decision networks, recognizing that: * Employers often delegate benefit authority to consultants or vendors * Direct employer access may be limited, episodic, or mediated * Influence is frequently exerted through trusted advisors rather than employers themselves * Establish sustained educational relationships with key decision influencers within each network, focused on: * Benefit design philosophy for high-cost, high-impact therapies * Total cost of care and episode-of-care economics * Workforce productivity, disability avoidance, and long-term value—not drug acquisition cost alone * Engage stakeholders ahead of annual benefit cycles to inform: * Cell therapy drug carve-out strategies * COE and site-of-care frameworks * Utilization management approaches for cell and gene therapies * Tailor messaging based on stakeholder role, ensuring relevance to: * HR and benefits leaders * Finance and CFO-aligned decision-makers * Consultant-led benefit committees and advisory councils * Position the organization as a credible, non-promotional thought partner in employer benefit strategy, filling the upstream education gap that otherwise defaults to cost-only narratives. ### Benefit Design Influence: * Engage...